Pure Biologics Spólka Akcyjna Cash Flow Conversion Efficiency
Pure Biologics Spólka Akcyjna cash flow conversion efficiency. Based on the latest financial reports, Pure Biologics Spólka Akcyjna (PUR) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-216.00K ≈ $-59.45K USD) by net assets (zł-19.39 Million ≈ $-5.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pure Biologics Spólka Akcyjna (2016–2024)
Cash flow conversion efficiency of Pure Biologics Spólka Akcyjna from 2016 to 2024. This chart illustrates how Pure Biologics Spólka Akcyjna's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PUR stock price for real-time trading data and today's change.
Pure Biologics Spólka Akcyjna Cash Flow Conversion Ratio Explained
Pure Biologics Spólka Akcyjna cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pure Biologics Spólka Akcyjna Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pure Biologics Spólka Akcyjna ranked by their cash flow conversion efficiency. Also see Pure Biologics Spólka Akcyjna market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IDOX plc
LSE:IDOX
|
0.002x |
|
Fidelity Asian Values
LSE:FAS
|
0.000x |
|
Hexicon AB
ST:HEXI
|
0.041x |
|
Mears Group plc
LSE:MER
|
0.354x |
|
Tesoro Minerals Corp.
V:TES
|
-0.178x |
|
Terregra Asia Energy PT
JK:TGRA
|
-0.007x |
|
Picton Property Income Ltd
LSE:PCTN
|
0.023x |
|
Skin Elements Ltd
AU:SKN
|
-0.699x |
Annual Cash Flow Conversion Efficiency for Pure Biologics Spólka Akcyjna (2016–2024)
The table below shows the annual cash flow conversion efficiency of Pure Biologics Spólka Akcyjna from 2016 to 2024. Review PUR FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł-13.12 Million ≈ $-3.61 Million |
zł-10.83 Million ≈ $-2.98 Million |
0.826x | +106.72% |
| 2023-12-31 | zł1.89 Million ≈ $520.98K |
zł-23.26 Million ≈ $-6.40 Million |
-12.288x | -1193.16% |
| 2022-12-31 | zł18.30 Million ≈ $5.04 Million |
zł-17.39 Million ≈ $-4.79 Million |
-0.950x | -56.11% |
| 2021-12-31 | zł39.49 Million ≈ $10.87 Million |
zł-24.04 Million ≈ $-6.61 Million |
-0.609x | -229.88% |
| 2020-12-31 | zł-2.89 Million ≈ $-794.54K |
zł-1.35 Million ≈ $-372.37K |
0.469x | -36.63% |
| 2019-12-31 | zł7.21 Million ≈ $1.99 Million |
zł5.33 Million ≈ $1.47 Million |
0.740x | +166.02% |
| 2018-12-31 | zł2.22 Million ≈ $611.22K |
zł-2.49 Million ≈ $-684.71K |
-1.120x | +91.75% |
| 2017-12-31 | zł209.77K ≈ $57.73K |
zł-2.85 Million ≈ $-784.16K |
-13.583x | -496.09% |
| 2016-12-31 | zł311.70K ≈ $85.78K |
zł-710.24K ≈ $-195.47K |
-2.279x | -- |
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more